ΕVŽ©ŒΘR‘ΜŒŸΈ(3)

RD’†‹…Χ–EŽΏR‘Μ( ANCA )

‹g@“c@‰λ@Ž‘*
@@@@@@@@@@@@@@@@@@@@@@
Antineutrophil Cytoplasmic Antibody(ANCA)

Masaharu YOSHIDA*

ANCA are associated with small sized vessel vasculitis; one subtype is an antibody against myeloperoxidase(MPO), which stains in a perinuclear pattern(P-ANCA) indirect immunofluorescence(IIF) using a neutrophil substrate, and the other subtype is an antibody against proteinase-3(PR-3), which stains in a diffuse granular cytoplasmic pattern ANCA by IIF. PR-3 ANCA is more specific in Wegenerfs granulomatosis(WG) than the other primary vasculitides. MPO-ANCA can be found in microscopic polyangiitis (MPA), Churg Strauss Syndromes(CSS), drug-induced vasculitis, and environmental factor-induced such as silicosis vasculitis more frequently than WG. The value of the IIF test for ANCA detection can be greatly increased by the addition of a standardized antigen-specific ELISA. The intra-assay and inter-assay CV of the MPO and PR-3 ELISA were 6.6 to 4.8%, respectively. Close ANCA titer correlation was shown between MPO-ANCA ELISA and the activity of ANCA associated vasulitis. Renal manifestations and pulmonary manifestations are observed in 70-90% of AAV as the initial manifestation. The changes in titers of ANCA seem to reflect disease activity in 60-70% of AAV patients. A combination of steroids and immunosuppressive drugs is effective in relieving the clinical symptoms of AAV.
[Rinsho Byori 51 : 644`648, 2003]

*The Department of Nephrology, Hachioji Medical Center of Tokyo Medical University, Hachioji 193-0998

yKey WordszC(PR-3) ANCACP(MPO)-ANCA(RD’†‹…Χ–EŽΏR‘Μ)Csmall vessel vasculitis(¬Œ^ŒŒŠΗ‰Š)CWegenerfs granulomatosis(ƒEƒFƒQƒi[“χ‰θŽξΗ)Cmicroscopic polyangitis(Œ°”χ‹Ύ“I‘½”­ŒŒŠΗ‰Š)

*“Œ‹žˆγ‰Θ‘εŠw”ͺ‰€Žqˆγ—ΓƒZƒ“ƒ^[t‘Ÿ‰Θ(§193-0998 ”ͺ‰€ŽqŽsŠΩ’¬1163)

E-mail :myoshida@tokyo-med.ac.jp